Bard Files Suit Under Pourchez Patent.Business Editors & Health/Medical Writers MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 19, 2003 C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE-BCR) announced today that its wholly-owned subsidiary, Bard Access Systems, Inc., along with Dr. Thierry Pourchez, has filed suit in the United States District Court United States District Court In the U.S., any of the 94 trial courts of general jurisdiction in the federal judicial system. Each state, as well as the District of Columbia and the Commonwealth of Puerto Rico, has at least one federal district court. for the Southern District of New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of on February 11, 2003 against Diatek, Inc. and Arrow International, Inc. The suit alleges that Arrow and Diatek's Cannon-Cath split-tip dialysis catheters infringe U.S. patent number 6,001,079, a patent owned by Dr. Pourchez and licensed exclusively to Bard Access Systems. Bard Access Systems acquired the exclusive license to the patent in October 2002. William H. Longfield, chairman and chief executive officer commented, "Bard is initiating this lawsuit in order to protect the valuable benefits of Dr. Pourchez's invention. The company will continue to vigorously defend its intellectual property." C.R. Bard, Inc., headquartered in Murray Hill, New Jersey
This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our September 30, 2002 Form 10-Q Form 10-Q See 10-Q. for a statement with regard to forward-looking statements, including disclosure of additional factors that could cause actual results to differ materially from those expressed or implied. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion